Financing ·
Hepion Pharmaceuticals, Inc. entered into securities purchase agreements on July 31, 2026, to sell and issue an…
HEPAHepion Pharmaceuticals, Inc.
Hepion Pharmaceuticals, Inc. entered into securities purchase agreements on July 31, 2026, to sell and issue an aggregate of 61,100,000 shares of common stock and warrants to purchase an equal number of shares in a private placement offering. The company received gross proceeds of $3,055,000 at an offering price of $0.05 per share. The transaction closed on August 3, 2026. Each warrant is exercisable at $0.06 per share for five years from issuance. Hepion Pharmaceuticals, Inc. operates in the biopharmaceutical industry, focusing on drug development.